FY2025 Earnings Forecast for Merus Issued By Leerink Partnrs

Merus N.V. (NASDAQ:MRUS) – Stock analysts at Leerink Partnrs upped their FY2025 EPS estimates for shares of Merus in a research note issued to investors on Sunday, November 2nd. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings per share of ($6.13) for the year, up from their prior forecast of ($6.63). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Merus’ current full-year earnings is ($3.85) per share. Leerink Partnrs also issued estimates for Merus’ Q4 2025 earnings at ($1.29) EPS, FY2026 earnings at ($5.28) EPS and FY2027 earnings at ($5.45) EPS.

Merus (NASDAQ:MRUS) last issued its earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The company had revenue of $8.83 million during the quarter, compared to analysts’ expectations of $9.77 million. Merus had a negative return on equity of 52.99% and a negative net margin of 673.31%.

MRUS has been the subject of a number of other research reports. BMO Capital Markets reiterated a “market perform” rating and set a $97.00 price objective on shares of Merus in a research report on Friday. Citigroup cut shares of Merus from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $101.00 to $97.00 in a research note on Monday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Merus in a report on Wednesday, October 8th. Guggenheim reaffirmed a “neutral” rating and set a $97.00 target price (down from $109.00) on shares of Merus in a report on Tuesday, September 30th. Finally, Lifesci Capital reiterated a “market perform” rating and issued a $97.00 price target on shares of Merus in a research report on Tuesday, September 30th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $92.35.

Merus Price Performance

NASDAQ MRUS opened at $95.04 on Wednesday. The stock has a market capitalization of $7.21 billion, a price-to-earnings ratio of -17.93 and a beta of 1.26. Merus has a 1-year low of $33.19 and a 1-year high of $95.30. The business’s fifty day moving average price is $82.21 and its 200-day moving average price is $64.45.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MRUS. Wellington Management Group LLP boosted its holdings in Merus by 34.9% in the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company’s stock worth $198,588,000 after buying an additional 1,220,519 shares during the period. Paradigm Biocapital Advisors LP boosted its stake in shares of Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company’s stock worth $141,831,000 after acquiring an additional 1,679,777 shares during the period. Holocene Advisors LP grew its position in shares of Merus by 18.8% during the second quarter. Holocene Advisors LP now owns 2,225,241 shares of the biotechnology company’s stock worth $117,048,000 after purchasing an additional 351,616 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Merus by 36.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 2,042,388 shares of the biotechnology company’s stock valued at $107,430,000 after purchasing an additional 541,168 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in Merus by 46.3% in the 2nd quarter. Federated Hermes Inc. now owns 1,528,587 shares of the biotechnology company’s stock worth $80,404,000 after purchasing an additional 483,962 shares in the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.